Cancer Therapy
Endoglin is a strong therapeutic target for angiogenesis inhibition
Published in Cancer Weekly, November 25th, 2003
"Among surface molecules expressed on endothelial cells, endoglin (CD105) is emerging as a prime vascular target for antiangiogenetic cancer therapy. CD105 is a cell membrane glycoprotein mainly expressed on endothelial cells and overexpressed on tumor-associated vascular endothelium, which functions as an accessory component of the transforming growth factor -beta receptor complex and is involved in vascular development and remodel," scientists in Italy report.
"Quantication of intratumoral microvessel density by CD105 staining and of circulating soluble CD105 has been suggested to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2003-11-25)
More Articles from Cancer Weekly
- Leukemia
Comprehensive gene profiles hold promise for improving outcomes - Stem-Cell Research
Researchers grow breast cancer tissue from transplanted mammary stem cells - Breast Cancer
Herpes simplex virus-1 treatment of primary tumors reduces metastatic cancer - Cancer Therapy
BOLD-contrast MRI monitors the vascular characteristics of tumors in real-time - Colorectal Cancer
Naturally occurring lignans useful in colorectal tumor therapy, chemoprevention - Oncology
Several risk factors are associated with hepatocellular carcinoma metastasis - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
